Contribution of Synercid (R) in clinical practice

Nosocomial pneumonia due to Gram-positive cocci: In a randomized multicentr ic trial comparing Synercid (R) with vancomycin, the cure rate (56,3 % vs 5 8,3 %) were equivalent in the 2 treatment arms. Treatment failures were als o similar: 44% vs 42%. Mortality (25% vs 22%) was likewise comparable, as w as tolerance. Skin and soft tissue infections: For erysipela, infections requiring surgic al dissection, post-trauma infections, postoperative wound infections, or d iabetes-related infections, the rate of success obtained in 2 open randomiz ed comparative multicentric trials was equivalent in the 2 treatment arms: 68.2% for Syncercid, 70.7% for the compared treatments. Emergency prescription: For E. faecium, the success rate was 74% based on c linical assessment and 70.5% based on bacteriological assessment. For meti- S S. aureus infections, the clinical success rate was 74% for all patients and 80% for bacteriologically evaluable patients; the bacteriological succe ss rate was 74% and 71% respectively. In case of infection due to C-MLSB me ti-R S. aureus, the percentage of clinical success was 89% for bacteriologi cally evaluable patients. (C) 2001, Massori, Paris.